Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID 40012066 **Collection Date** 23/03/2024 9:55AM 23/03/2024 10:04AM Age/Gender 39 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9413073700

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: FI. Plasma

 BLOOD GLUCOSE (FASTING)
 102.1
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 115.4 mg/dl Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl

Pre – Diabetic: - 140-199 mg, Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH Sample: Serum

Т3	1.310	ng/mL	0.970 - 1.690
T4	10.60	ug/dl	5.53 - 11.00
TSH	0.92	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name	Mrs. NEETU AZAD RAMAN	Lab No	4028353
UHID	40012066	Collection Date	23/03/2024 9:55AM
Age/Gender IP/OP Location	39 Yrs/Female	Receiving Date	23/03/2024 10:04AM
	O-OPD	Report Date	23/03/2024 2:49PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9413073700		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.62	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.36	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.26	mg/dl	0.00 - 0.30	
SGOT	45.0 H	U/L	0.0 - 32.0	
SGPT	60.9 H	U/L	0.0 - 33.0	

g/dl

6.6 - 8.7

3.5 - 5.2

g/dl **GLOBULIN** 2.5 1.8 - 3.6 ALKALINE PHOSPHATASE 141 H U/L 35 - 104 A/G RATIO Ratio 1.5 - 2.5 **GGTP** 47.0 H U/L 0.0 - 40.0

6.9

4.4

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

TOTAL PROTEIN

ALBUMIN

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID **Collection Date** 23/03/2024 9:55AM 40012066 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female Report Date O-OPD **IP/OP Location** 23/03/2024 2:49PM Referred By Dr. EHS CONSULTANT **Report Status** Final 9413073700

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation: Determinations of direct bilirubin measure mainly conjugated. water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation: -SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bluret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder. ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in

hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

Mobile No.

TOTAL CHOLESTEROL	127		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	38.7		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	69.9		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	18	mg/dl	10 - 50
TRIGLYCERIDES	91		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3	%	

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID **Collection Date** 23/03/2024 9:55AM 40012066 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM Dr. EHS CONSULTANT Final

Referred By Report Status

Mobile No. 9413073700

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation: -The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

25.2	mg/dl	16.60 - 48.50
11.8	mg/dl	6 - 20
0.60	mg/dl	0.50 - 0.90
140.1	mmol/L	136 - 145
3.91	mmol/L	3.50 - 5.50
103.8	mmol/L	98 - 107
2.85	mg/dl	2.4 - 5.7
9.30	mg/dl	8.60 - 10.00
	11.8 0.60 140.1 3.91 103.8 2.85	11.8 mg/dl 0.60 mg/dl 140.1 mmol/L 3.91 mmol/L 103.8 mmol/L 2.85 mg/dl

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 4 Of 11

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID **Collection Date** 23/03/2024 9:55AM 40012066 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female Report Date O-OPD **IP/OP Location** 23/03/2024 2:49PM Referred By Dr. EHS CONSULTANT **Report Status** Final

BIOCHEMISTRY

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.
URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.
SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.
POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

9413073700

Sample: WHOLE BLOOD EDTA

HBA1C 5.9 % < 5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - Turbidimetric\ inhibition\ immunoassay\ (TINIA)}$

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Mobile No.

MBBS | MD | INCHARGE PATHOLOGY

Page: 5 Of 11

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID 40012066 **Collection Date** 23/03/2024 9:55AM 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "B" Rh Positive

Mobile No.

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

9413073700

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Lab No 4028353 Mrs. NEETU AZAD RAMAN **Collection Date** 23/03/2024 9:55AM UHID 40012066 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9413073700

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	
BACTERIA	NIL		NIL	
OHTERS	NIL		NIL	

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID 40012066 **Collection Date** 23/03/2024 9:55AM 23/03/2024 10:04AM Age/Gender 39 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final 9413073700 Mobile No.

Methodology:-

Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 UHID 40012066 **Collection Date** 23/03/2024 9:55AM 23/03/2024 10:04AM Age/Gender 39 Yrs/Female **Receiving Date** Report Date **IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Rar	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.5	g/dl	12.0 - 15.0	
PACKED CELL VOLUME(PCV)	38.9	%	36.0 - 46.0	
MCV	83.5	fl	82 - 92	
MCH	26.8 L	pg	27 - 32	
MCHC	32.1	g/dl	32 - 36	
RBC COUNT	4.66	millions/cu.mm	3.80 - 4.80	
TLC (TOTAL WBC COUNT)	8.33	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	72.9	%	40 - 80	
LYMPHOCYTE	20.5	%	20 - 40	
EOSINOPHILS	2.6	%	1 - 6	
BASOPHIL	0.2 L	%	1 - 2	
MONOCYTES	3.8	%	2 - 10	
PLATELET COUNT	2.11	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV: - Method: - Calculation bysysmex.

MCH: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

MCHC: - Method: - Calculation bysysmex.

REC COUNT: - Method: - Hydrodynamicfocusing.Interpretation: - Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 25 H mm/1st hr 0 - 15

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Mobile No.

9413073700

Patient Name Mrs. NEETU AZAD RAMAN Lab No 4028353 23/03/2024 9:55AM UHID 40012066 **Collection Date** 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9413073700

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Page: 10 Of 11

Mrs. NEETU AZAD RAMAN **Patient Name** Lab No 4028353 UHID 40012066 **Collection Date** 23/03/2024 9:55AM 23/03/2024 10:04AM Age/Gender **Receiving Date** 39 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:49PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9413073700

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY CHEST P. A. VIEW

Both lung fields areclear.

Both CP angles areclear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is withinnormal limits.

Visualized bony thoraxis unremarkable.

Correlate clinically & with other related investigations.

End Of Report

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Genery ..

Dr. SURESH KUMAR SAINI

MBBS,MD RADIOLOGIST

Page: 11 Of 11

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40012066 (8924)	RISNo./Status:	4028353/
Patient Name:	Mrs. NEETU AZAD RAMAN	Age/Gender:	39 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	23/03/2024 9:19AM/ OPSCR23- 24/16490	Scan Date :	
Report Date:	23/03/2024 12:29PM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal								
IVSD	10.7	6-12mm		LVIDS	25.0	20-40mm		
LVIDD	38.2		32-	57mm		LVPWS	16.8	mm
LVPWD	11.2		6-1	l2mm		AO	29.1	19-37mm
IVSS	15.3]	mm		LA	31.6	19-40mm
LVEF	62-64		>	55%		RA	•	mm
	DOPPLER	R MEA	SUREN	IENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY		VELOC	CITY (m/	's)	GRADIENT		REGURGITATION
			, ,		(mmHg)			
MITRAL	NORMAL	E	0.90	e'	-	-		NIL
VALVE		A	0.66	E/e'	-			
TRICUSPID	NORMAL		E	0.0	69	-		NIL
VALVE			A	0	52	-		
		A 0.53						
AORTIC	NORMAL	1.46		-		NIL		
VALVE								
PULMONARY	NORMAL	0.82				NIL		
VALVE						-		

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40012066 (8924)	RISNo./Status:	4028353/
Patient Name:	Mrs. NEETU AZAD RAMAN	Age/Gender:	39 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	23/03/2024 9:19AM/ OPSCR23- 24/16490	Scan Date :	
Report Date :	23/03/2024 11:03AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver: Normal in size & shows increased parenchymal echotexture. No obvious significant

focal parenchymal mass lesion noted. Intrahepatic biliary radicals are not dilated.

Portal vein is normal.

Gall Bladder: Multiple calculi seen within the lumen, largest measuring approx. 6-7mm. Wall

thickness is normal. CBD is normal.

Pancreas: Normal in size & echotexture.

Spleen: Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

Uterus: Normal in size, shape & anteverted in position. Endometrial thickness is normal.

Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.

Both ovaries: Bilateral ovaries are normal in size, shape & volume.

Others: No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

Fatty liver.

Cholelithiasis.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

Incharge & Senior Consultant Radiology

MBBS, DMRD, DNB

Reg. No. 26466, 16307

Patient Name	Mrs. NEETU AZAD RAMAN	Lab No	4028353
UHID	40012066	Sample Date	23/03/2024 1:08PM
Age/Gender	39 Yrs/Female	Report Date	23/03/2024 2:56PM
Prescribed By	Dr. EHS CONSULTANT	Bed No / Ward	OPD
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Company	Mediwheel - Arcofemi Health Care Ltd.		

CYTOLOGY

CYTOLOGY*

Type of Specimen Pap smear (Conventional)

No. of smears examined Two

Satisfactory for evaluation.

Adequacy Adequate Endocervical cells Not seen.

Inflammation Mild acute inflammation

Organisms Not seen Epithelial cell abnormality Not seen

Others -

Impression Negative for intraepithelial lesion / malignancy.

Note: Test marked as * are not accredited by NABL

Bethesda2014

-----** End Of Report **-----

Aldernay Varnay

Dr. ABHINAY VERMA
MBBS|MD|INCHARGE PATHOLOGY